CRT 2026

BEYOND THE GUIDELINES | DE-ESCALATION OF ANTIPLATELET THERAPY

Moderator(s)

• 

  George Dangas, MD, MACC, MSCAI

  PROFESSOR OF CARDIOLOGY
  The Mount Sinai Hospital
  New York, New York, United States

  Disclosure(s): No financial relationships to disclose
• 

  Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

  Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
  Icahn School of Medicine at Mount Sinai, New York
  New York, New York, United States

  Disclosure(s): Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (Vice President, BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Stock Options [in privately held companies] (Ongoing); Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ;: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): No Fees (Ongoing)

Panel Discussant(s)

• 

  Usman Baber, MD, MS

  Professor of Medicine
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma, United States

  Disclosure information not submitted.
• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure information not submitted.
• 

  Adnan Kastrati, MD

  Senior Consultant, Head of Catheterization Laboratory
  Deutsches Herzzentrum Muenchen
  Munich, Bayern, Germany

  Disclosure(s): No financial relationships to disclose
• 

  Sanjay Kaul, MD

  Attending Cardiologist
  Cedars-Sinai Medical Center
  Los Angeles, California, United States

  Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Terminated, October 1, 2023); Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Bayer HealthCare: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Terminated, November 1, 2023); medtronic.: Consulting Fees (e.g., advisory boards) (Terminated, August 1, 2023); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); Novo Nordisk: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Ron Waksman, MD, MSCAI

  Director, Cardiovascular Research and Advanced Education
  MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
  Washington, District of Columbia, United States

  Disclosure information not submitted.
• 

  Sunil V. Rao, MD, FSCAI

  Professor of Medicine
  NYU Langone Health System
  New York, New York, United States

  Disclosure(s): No financial relationships to disclose